Akero Therapeutics, Inc. AKRO
We take great care to ensure that the data presented and summarized in this overview for Akero Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKRO
View all-
Wellington Management Group LLP Boston, MA7.38MShares$382 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$356 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$313 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$290 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$271 Million5.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$224 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$192 Million0.0% of portfolio
-
State Street Corp Boston, MA2.34MShares$121 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.84MShares$95.3 Million0.02% of portfolio
-
Alkeon Capital Management LLC New York, NY1.76MShares$91.3 Million0.1% of portfolio
Latest Institutional Activity in AKRO
Top Purchases
Top Sells
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at AKRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.77%
|
$500,000
$50.21 P/Share
|
|
Feb 18
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.65%
|
$210,000
$21.1 P/Share
|
|
Feb 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-0.85%
|
$1,590,000
$53.74 P/Share
|
|
Feb 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,750
-5.07%
|
$1,050,000
$56.63 P/Share
|
|
Feb 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+9.03%
|
$393,750
$21.1 P/Share
|
|
Feb 03
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.93%
|
$530,000
$53.81 P/Share
|
|
Jan 30
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
200,000
+16.67%
|
$9,600,000
$48.0 P/Share
|
|
Jan 27
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
102,664
-13.17%
|
$5,749,184
$56.04 P/Share
|
|
Jan 27
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
102,664
+15.4%
|
$1,231,968
$12.29 P/Share
|
|
Jan 27
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.35%
|
$1,650,000
$55.66 P/Share
|
|
Jan 27
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
5,000
-12.99%
|
$285,000
$57.03 P/Share
|
|
Jan 27
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.41%
|
$76,000
$19.87 P/Share
|
|
Jan 27
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
31,250
-5.44%
|
$1,718,750
$55.78 P/Share
|
|
Jan 27
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+7.48%
|
$625,000
$20.49 P/Share
|
|
Jan 24
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,064
+14.16%
|
$258,384
$6.36 P/Share
|
|
Jan 23
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+6.28%
|
$0
$0.62 P/Share
|
|
Jan 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
14,000
-7.6%
|
-
|
|
Jan 02
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.38%
|
$280,000
$28.03 P/Share
|
|
Dec 31
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
234
+0.67%
|
$4,446
$19.69 P/Share
|
|
Dec 26
2024
|
Timothy Rolph Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
14,100
-7.11%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 238K shares |
|---|---|
| Exercise of conversion of derivative security | 1.16M shares |
| Open market or private purchase | 200K shares |
| Open market or private sale | 1.16M shares |
|---|---|
| Bona fide gift | 28.1K shares |